Kosuke Kashiwabara Selected Research

Systemic Scleroderma (Systemic Sclerosis)

11/2022	Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
8/2022	Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
1/2022	Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
7/2021	Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kosuke Kashiwabara Research Topics

Disease

20	Neoplasms (Cancer) 01/2024 - 12/2008
20	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2021 - 01/2007
9	Breast Neoplasms (Breast Cancer) 12/2022 - 09/2016
7	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 07/2002
6	Lung Neoplasms (Lung Cancer) 11/2022 - 05/2013
6	Adenocarcinoma of Lung 10/2020 - 12/2008
5	Hemorrhage 01/2024 - 01/2008
5	Colorectal Neoplasms (Colorectal Cancer) 07/2023 - 07/2017
5	Adenocarcinoma 01/2020 - 12/2008
4	Systemic Scleroderma (Systemic Sclerosis) 11/2022 - 07/2021
4	Stomatitis 04/2021 - 09/2016
3	COVID-19 01/2024 - 03/2023
3	Colonic Neoplasms (Colon Cancer) 06/2023 - 01/2017
3	Disease Progression 03/2023 - 09/2016
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023 - 10/2022
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2022 - 03/2012
3	Airway Obstruction (Choking) 12/2022 - 09/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 01/2023
2	Body Weight (Weight, Body) 09/2023 - 05/2013
2	Pneumonia (Pneumonitis) 03/2023 - 01/2021
2	Peripheral Nervous System Diseases (PNS Diseases) 12/2022 - 02/2021
2	Sclerosis 11/2022 - 07/2021
2	Rheumatic Diseases (Rheumatism) 08/2022 - 07/2021
2	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 11/2017
2	Neoplasm Metastasis (Metastasis) 09/2021 - 02/2019
2	Infections 08/2021 - 07/2021
2	Mucositis 04/2021 - 01/2020
2	Neutropenia 01/2018 - 05/2013
2	Idiopathic Interstitial Pneumonias 02/2015 - 01/2015
2	Fibrosis (Cirrhosis) 01/2008 - 02/2006
1	Type 2 Diabetes Mellitus (MODY) 02/2024
1	Bacterial Pneumonia 01/2024
1	Hypoxia (Hypoxemia) 01/2024
1	Diabetic Foot 10/2023
1	Ulcer 10/2023
1	Phlebitis 09/2023
1	Renal Insufficiency (Renal Failure) 07/2023
1	Peritoneal Neoplasms 06/2023
1	Edema (Dropsy) 03/2023
1	Pneumococcal Pneumonia 08/2022

Drug/Important Bio-Agent (IBA)

7	ErbB Receptors (EGF Receptor)IBA 01/2021 - 11/2016
5	Everolimus FDA Link 12/2021 - 09/2016
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2006
4	130-nm albumin-bound paclitaxelIBA 12/2022 - 02/2021
4	Rituximab (Mabthera)FDA Link 11/2022 - 07/2021
4	Estrogen ReceptorsIBA 04/2021 - 09/2016
4	exemestane (Aromasin)FDA Link 04/2021 - 09/2016
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2019 - 04/2012
3	Bevacizumab (Avastin)FDA Link 06/2023 - 04/2019
3	pitavastatin (itavastatin)FDA Link 01/2023 - 10/2022
2	nafamostatIBA 09/2023 - 03/2023
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2023 - 06/2023
2	Paclitaxel (Taxol)FDA LinkGeneric 06/2023 - 05/2013
2	RNA (Ribonucleic Acid)IBA 04/2023 - 01/2017
2	LipidsIBA 01/2023 - 10/2022
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 10/2022
2	taxaneIBA 12/2022 - 01/2022
2	B7-H1 AntigenIBA 11/2022 - 01/2021
2	Oxygen (Dioxygen)IBA 06/2022 - 09/2021
2	Serum AlbuminIBA 01/2022 - 01/2020
2	AnticoagulantsIBA 12/2021 - 11/2019
2	osimertinibIBA 07/2021 - 01/2021
2	Dexamethasone (Maxidex)FDA LinkGeneric 04/2021 - 01/2020
2	Ointments (Pastes)IBA 04/2021 - 04/2021
2	LigandsIBA 01/2021 - 10/2018
2	AlbuminsIBA 01/2021 - 11/2017
2	Gefitinib (Iressa)FDA Link 01/2021 - 01/2017
2	Hormones (Hormone)IBA 01/2020 - 03/2018
2	Immune Checkpoint InhibitorsIBA 01/2020 - 08/2018
2	EnzymesIBA 01/2018 - 07/2002
2	Carboplatin (JM8)FDA LinkGeneric 05/2013 - 03/2012
1	Antiviral Agents (Antivirals)IBA 09/2023
1	Leucovorin (Folinic Acid)FDA Link 06/2023
1	Capecitabine (Xeloda)FDA Link 06/2023
1	Fluorouracil (Carac)FDA LinkGeneric 06/2023
1	DNA (Deoxyribonucleic Acid)IBA 04/2023
1	favipiravirIBA 03/2023
1	Troponin IIBA 01/2023
1	omega-Chloroacetophenone (Mace)IBA 01/2023
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2023
1	pro-brain natriuretic peptide (1-76)IBA 01/2023
1	pembrolizumabIBA 11/2022
1	LDL CholesterolIBA 10/2022

Therapy/Procedure

18	Therapeutics 01/2023 - 03/2018
17	Drug Therapy (Chemotherapy) 01/2024 - 03/2012
8	Adjuvant Chemotherapy 07/2023 - 12/2008
5	Radiotherapy 06/2021 - 02/2019
4	Stents 01/2024 - 09/2019
2	Drug Tapering 07/2023 - 01/2020
2	Catheters 07/2022 - 01/2007
2	Conscious Sedation 06/2022 - 09/2021
2	Chemoradiotherapy 06/2021 - 01/2021
2	Pleurodesis 02/2020 - 01/2020
1	Glycemic Control 02/2024
1	Long-Term Care 01/2024
1	CARE protocol 10/2023
1	Aftercare (After-Treatment) 08/2023
1	Duration of Therapy 07/2023
1	Indwelling Catheters (Indwelling Catheter) 03/2023